Clinical relevance of CD10, BCL-6 and multiple myeloma-1 expression in diffuse large B-cell lymphomas in Malaysia

Pathology International

Volumn 58, Issue 9, 2008, Pages 572-579

  Peh, Suat Cheng ^a   Gan, Gin Gin ^a   Lee, Lin Kiat ^a   Eow, Geok Im ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

BCL 2; BCL 6; CD10; Diffuse large B cell lymphoma; EBV; MUM 1

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON REGULATORY FACTOR 4; PREDNISOLONE; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; GENETIC HETEROGENEITY; GERMINAL CENTER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALAYSIA; MALE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; SCORING SYSTEM; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON REGULATORY FACTORS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALAYSIA; MALE; MIDDLE AGED; NEPRILYSIN; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 49749115784     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2008.02273.x     Document Type: Article

References (37)

1. Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In : Jaffe ES, Harris NC, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon : IARC Press, 2001 171 4.
2. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol 2001 13 : 325 34.
3. Peh SC. Host ethnicity influences non-Hodgkin's lymphoma (NHL) subtype frequency and Epstein-Barr virus association rate: The experience of a multi-ethnic patient population in Malaysia. Histopathology 2001 38 : 458 65.
4. Colomo L, Lopez-Guillermo A, Perales M et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003 101 : 78 84.
5. Isaacson PG, Campo E. Prognostic factors in non-Hodgkin's lymphomas. Rev Esp Patol 1999 32 : 305 10.
6. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000 403 : 503 11.
7. Levene AP, Morgan GJ, Davies FE. The use of genetic microarray analysis to classify and predict prognosis in haematological malignancies. Clin Lab Haematol 2003 25 : 209 20.
8. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002 346 : 1937 47.
9. McIntosh GG, Lodge AJ, Watson P et al. NCL-CD10-270: A new monoclonal antibody recognizing CD10 in paraffin-embedded tissue. Am J Pathol 1999 154 : 77 82.
10. Dogan A, Munson P, Isaacson PG. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 2000 24 : 846 52.
11. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000 13 : 199 212.
12. Fukuda T, Yoshida T, Okada S et al. Disruption of the Bcl6 gene results in an impaired germinal centre formation. J Exp Med 1997 186 : 439 48.
13. Falini B, Fizzotti M, Pucciarini A et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal centre B cells, plasma cells, and activated T-cells. Blood 2000 95 : 2084 92.
14. McCluggage WG, Catherwood M, Alexander HD, McBride HA, Smith MEF, Morris TCM. Immunohistochemical expression of CD10 and t(14;18) chromosomal translocation may be indicators of follicle centre cell origin in nodal diffuse large B-cell lymphoma. Histopathology 2002 41 : 414 20.
15. Ree HJ, Yang WI, Kim CW et al. Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: Significance of Bcl-6 expression patterns in identifying germinal centre B-cell lymphoma. Hum Pathol 2001 32 : 954 62.
16. Wang X, Li Z, Naganuma A, Ye BH. Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B-cell lymphomas. Proc Natl Acad Sci USA 2002 99 : 15 018 23.
17. Dent AL, Vasanwala FH, Toney LM. Regulation of gene expression by the proto-oncogene BCL-6. Crit Rev Oncol Hematol 2002 41 : 1 9.
18. Carbone A, Gloghini A, Larocca LM et al. Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 2001 97 : 744 51.
19. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004 103 : 275 82.
20. Jarrett RF, Stark GL, White J et al. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: A population-based study. Blood 2005 106 : 2444 51.
21. Park S, Lee J, Ko YH et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007 110 : 972 8.
22. Kwon JM, Park YH, Kang JH et al. The effect of Epstein-Barr virus status on clinical outcome in hodgkin's lymphoma. Ann Hematol 2006 85 : 463 8.
23. Cheng AL, Su IJ, Chen YC, Uen WC, Wang CH. Characteristic clinicopathologic features of Epstein-Barr virus-associated peripheral T cell lymphoma. Cancer 1993 72 : 909 16.
24. Kim JE, Kim YA, Jeon YK, Park SS, Heo DS, Kim CW. Comparative analysis of NK/T cell lymphoma and peripheral T-cell lymphoma in Korea: Clinicopathological correlations and analysis of EBV strain type and 30-bp deletion variant LMP1. Pathol Int 2003 53 : 735 43.
25. Chang CC, McClintock A, Cleveland RP et al. Immunohistochemical expression patterns of germinal centre and activated B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004 28 : 464 70.
26. Oh YH, Park CK. Prognostic evaluation of nodal diffuse large B-cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor. J Korean Med Sci 2006 21 : 397 405.
27. De Paepe P, Achten R, Verhoef G et al. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol 2005 23 : 7060 68.
28. Sukpanichnant S. Analysis of 1983 cases of malignant lymphoma in Thailand according to the World Health Organization classification. Hum Pathol 2004 35 : 224 30.
29. Lossos IS, Czerwinski DK, Alizadeh AA et al. Prediction of survival in diffuse large B cell lymphoma based on the expression of six genes. N Engl J Med 2004 350 : 1828 37.
30. Rantanen S, Monni O, Joensuu H et al. Causes and consequences of BCL2 over-expression in diffuse large B-cell lymphoma. Leuk Lymphoma 2001 42 : 1089 98.
31. Barrans S, Carter I, Owen R et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002 99 : 1136 43.
32. Hermine O, Haioun C, Lepage E et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 1996 87 : 265 72.
33. Iqbal J, Neppalli VT, Wright G et al. BCL2 expression is a prognostic marker for the activated B-Cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006 24 : 961 8.
34. Lossos IS, Jones CS, Wamke R et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001 98 : 945 51.
35. Chen YW, Hu XT, Liang AC et al. High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations in gastric lymphoma. Blood 2006 108 : 2373 83.
36. Jn W, Weller EA, Horning SJ et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: A prospective correlative study. Blood 2006 107 : 4207 13.
37. Chang CC, Kampalath B, Schultz C et al. Expression of p53, c-Myc or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals. Arch Pathol Lab Med 2003 127 : 208 12.